

# Pharmacy & Therapeutics Committee Schedule

Meetings will be held virtually

For information on AHCCCS Pharmacy & Therapeutics (P&T) Committee public testimony and class reviews, visit [Prime Therapeutics](#). Additional class reviews may be added as needed.

P&T Committee Schedule	
Date	Class Review
January 15, 2025	<p><b>Non-Supplemental Rebate Class Review:</b></p> <ul style="list-style-type: none"> <li>• Androgenic Agents</li> <li>• Antidepressants, Other</li> <li>• Antidepressants, SSRIs</li> <li>• Antivirals, Topical</li> <li>• Bone Resorption Suppression and Related Agents</li> <li>• Bronchodilators, Beta Agonists</li> <li>• Colony Stimulating Factors</li> <li>• Enzyme Replacement, Gaucher Disease</li> <li>• Erythropoiesis Stimulating Proteins</li> <li>• Hypoglycemics, Alpha Glucosidase Inhibitors</li> <li>• Hypoglycemics, Metformins</li> <li>• Hypoglycemics, SGLT2s</li> <li>• Immune Globulins</li> <li>• Oncology, Oral – Hematologic</li> <li>• Ophthalmics, Anti-inflammatory/ Immunomodulators</li> <li>• Oral and Inhaled Pulmonary Arterial Hypertension Agents</li> <li>• Otic Antibiotics</li> <li>• Thrombopoiesis Stimulating Agents</li> <li>• Ulcerative Colitis</li> </ul>
May 21, 2025	<p><b>Supplemental Rebate Classes Review:</b></p> <ul style="list-style-type: none"> <li>• Analgesics, Long-Acting Narcotic</li> <li>• Antibiotics, Inhaled</li> <li>• Antimigraine Agents, Other</li> <li>• Antipsychotics, Atypical Long-Acting Injectable</li> <li>• Antipsychotics, Oral Atypical (2nd Gen Only)</li> <li>• Colony Stimulating Factors</li> </ul>

	<ul style="list-style-type: none"> <li>• COPD Agents</li> <li>• Cytokine and CAM Antagonists</li> <li>• Glucagon Agents</li> <li>• Glucocorticoids, Inhaled</li> <li>• Growth Hormone</li> <li>• Hepatitis C Agents</li> <li>• HIV Aids</li> <li>• Hypoglycemics (Insulin and Related Agents)</li> <li>• Hypoglycemics, Incretin Mimetics/Enhancers</li> <li>• Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)</li> <li>• Movement Disorders</li> <li>• Multiple Sclerosis Agents</li> <li>• Opioid Dependence Treatments</li> <li>• Pancreatic Enzymes</li> <li>• Stimulants and Related Agents</li> </ul>
<p><b>October 22, 2025</b></p>	<p><b>Non-Supplemental Repeat Classes Review:</b></p> <ul style="list-style-type: none"> <li>• Antimigraine Agents-Triptans</li> <li>• Leukotriene Modifiers</li> <li>• Phosphate Binders</li> <li>• Sedative Hypnotics</li> <li>• Topical Steroids by Potency (low, medium, high, very high)</li> <li>• Antifungals-Oral</li> <li>• Antifungals- Topicals</li> <li>• Beta Blockers</li> <li>• BPH Treatments</li> <li>• Calcium Channel Blockers</li> <li>• HIV-AIDS</li> <li>• Movement Disorders</li> </ul>
<p><b>January 13, 2026</b></p>	<p><b>Non-Supplemental Rebate Class Review:</b></p> <ul style="list-style-type: none"> <li>• Androgenic Agents</li> <li>• Antidepressants, Other</li> <li>• Antidepressants, SSRIs</li> <li>• Antivirals, Topical</li> <li>• Bone Resorption Suppression and Related Agents</li> <li>• Bronchodilators, Beta Agonists</li> </ul>

	<ul style="list-style-type: none"> <li>• Colony Stimulating Factors</li> <li>• Enzyme Replacement, Gaucher Disease</li> <li>• Erythropoiesis Stimulating Proteins</li> <li>• Hypoglycemics, Alpha Glucosidase Inhibitors</li> <li>• Hypoglycemics, Metformins</li> <li>• Hypoglycemics, SGLT2s</li> <li>• Immune Globulins</li> <li>• Oncology, Oral – Hematologic</li> <li>• Ophthalmics, Anti-inflammatory/ Immunomodulators</li> <li>• Oral and Inhaled Pulmonary Arterial Hypertension Agents</li> <li>• Otic Antibiotics</li> <li>• Thrombopoiesis Stimulating Agents</li> <li>• Ulcerative Colitis</li> </ul>
<p><b>May 19, 2026</b></p>	<p><b>Supplemental Rebate Classes Review:</b></p> <ul style="list-style-type: none"> <li>• Inhaled Glucocorticoids</li> <li>• Opiate Dependence Treatments</li> <li>• Hypoglycemics - Incretin Mimetics/Enhancers</li> <li>• Hypoglycemics -Insulin and Related Agents</li> <li>• COPD Agents</li> <li>• Antipsychotics - Oral Atypicals 2nd Generation</li> <li>• Antipsychotics - Atypical Long-Acting Injectables</li> <li>• Stimulants and Related Agents</li> <li>• Pancreatic Enzymes</li> <li>• Anticoagulants</li> <li>• Hepatitis C Agents</li> <li>• Cytokine and CAM Antagonists</li> <li>• Long Acting Narcotic Analgesics</li> <li>• Growth Hormone</li> <li>• Epinephrine, Self-Injected</li> <li>• Antibiotics, Inhaled</li> <li>• Progestational Agents</li> <li>• Antimigraine – CGRPs</li> <li>• Skin Substitutes</li> </ul>
<p><b>October 21, 2026</b></p>	<p><b>Non-Supplemental Repeat Classes Review:</b></p> <ul style="list-style-type: none"> <li>• Antimigraine Agents-Triptans</li> <li>• Leukotriene Modifiers</li> <li>• Phosphate Binders</li> </ul>

	<ul style="list-style-type: none"> <li>• Sedative Hypnotics</li> <li>• Topical Steroids by Potency (low, medium, high, very high)</li> <li>• Antifungals-Oral</li> <li>• Antifungals- Topicals</li> <li>• Beta Blockers</li> <li>• BPH Treatments</li> <li>• Calcium Channel Blockers</li> <li>• HIV-AIDS</li> <li>• Movement Disorders</li> </ul>
<p><b>January 26, 2026</b></p>	<p><b>Non-Supplemental Rebate Class Review:</b></p> <ul style="list-style-type: none"> <li>• Androgenic Agents</li> <li>• Antidepressants, Other</li> <li>• Antidepressants, SSRIs</li> <li>• Antivirals, Topical</li> <li>• Bone Resorption Suppression and Related Agents</li> <li>• Bronchodilators, Beta Agonists</li> <li>• Colony Stimulating Factors</li> <li>• Enzyme Replacement, Gaucher Disease</li> <li>• Erythropoiesis Stimulating Proteins</li> <li>• Hypoglycemics, Alpha Glucosidase Inhibitors</li> <li>• Hypoglycemics, Metformins</li> <li>• Hypoglycemics, SGLT2s</li> <li>• Immune Globulins</li> <li>• Oncology, Oral – Hematologic</li> <li>• Ophthalmics, Anti-inflammatory/ Immunomodulators</li> <li>• Oral and Inhaled Pulmonary Arterial Hypertension Agents</li> <li>• Otic Antibiotics</li> <li>• Thrombopoiesis Stimulating Agents</li> <li>• Ulcerative Colitis</li> </ul>